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Abstract
Background: Previous studies have shown conflicting results for the association between TLR4
polymorphism (Asp299Gly) and lung function. We investigated the influence of TLR4 Asp299Gly,
a polymorphism, on lung function in a community population.
Methods: In 2003, a cross-sectional survey was conducted to assess the respiratory health of
residents living in and around the town of Humboldt, Saskatchewan, Canada. There were 2090
adults age 18-79 years who completed a questionnaire that included a medical and smoking history,
as well as socio-economic and lifestyle variables. Genetic information and lung function test
measurements were available on 1725 subjects (754 males and 971 females) of the 2090
respondents. These subjects were selected for further analysis to investigate the association
between TLR4 Asp299Gly genotype and forced expiratory volume in the first second in liters
(FEV1), forced vital capacity in liters (FVC), FEV1/FVC ratio, and forced expiratory flow rate in
liters/second (FEF25-75). Multivariable linear regression analysis was used to investigate associations.
Results: Adjusted mean values of FEV1 and FVC were significantly different between TLR4 wild
type and TLR4 variant groups [Mean ± S.E.: (TLR4 wild type - FEV1: 3.18 ± 0.02, FVC: 3.95 ± 0.03;
TLR4 variant - FEV1: 3.31 ± 0.06, FVC: 4.14 ± 0.07)]. Based on multivariable regression analysis, we
observed that body mass index (BMI) was associated with decreased FEV1/FVC ratio and FEF25-75
in TLR4 variant group but not in wild type group.
Conclusion: BMI may modify the associations of TLR4 Asp299Gly polymorphism with FEV1/FVC
ratio and FEF25-75.
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Background
Toll-like receptor (TLR) proteins have been shown to play
an important role in both innate and adaptive immune
response in higher vertebrates and have been involved in
a number of lung-associated immune responses and
pathologies [1-7]. The role of TLR proteins in lung-associ-
ated conditions such as airway hyperactivity, allergic
asthma, tuberculosis and exposure to endotoxin has been
studied [6,7]. TLR4 has been shown to play a role in aller-
gic asthma, perhaps by modulating the Th1 vs. Th2
responses [8]. TLR4 polymorphisms Asp299Gly and
Thr399Ile have been associated with the development of
respiratory diseases [5]. However, LeVan et al. [9] reported
no association between TLR4 Asp299Gly and lung func-
tion or wheeze. The prevalence of TLR4 Asp299Gly poly-
morphism has been demonstrated to be approximately
10-12% in populations dominated by Caucasians [(Ren-
nie DC, Chen Y, Pahwa P, Burch LH, Bharadwaj L, Grover
VK, Schwartz DA, Dosman JA: Gender-related associa-
tions between toll-like 4 receptor 299 polymorphism and
respiratory outcomes, submitted), [3]].
It has been shown that the TLR4 gene may have a major
influence on adiposity [10], and metabolic syndrome [11]
in addition to its well known role in the immune
response. An association between body mass index and
reduced lung function has been demonstrated [12,13]. A
few studies have shown an association between waist cir-
cumference, a component of the metabolic syndrome,
adiposity and impaired lung function [14-17]. It has been
suggested that waist circumference is a better indicator of
metabolic syndrome compared to percentage fat [17]. The
association between TLR4 Asp299Gly polymorphism and
lung function in relation to obesity (in terms of BMI or
waist circumference or other metabolic syndrome compo-
nents) is an uncharted area. The aim of this paper was to
investigate a possible association between the Asp299Gly
polymorphism of the TLR4 and the lung function meas-
urements (FEV1, FVC, FEF25_75, and FEV1/FVC ratio) in the
presence of potential effect modifiers and/or confound-
ers.
Methods
Recruitment
The cross-sectional community study of adults was con-
ducted in 2003 in Humboldt, Saskatchewan, Canada
through a household canvass of town residents and
through a mail out to rural residents in the surrounding
municipality. All participants brought completed ques-
tionnaires to a health screening centre located in the
town. The study protocol has been previously described
[18]. Briefly, 2090 adults in the age group 19-79 years
completed a questionnaire that included medical history,
smoking history, socio-economic and life style variables.
Subjects signed a witnessed informed consent. Prior to the
study, approval by the Biomedical Research Ethics Board
of the University of Saskatchewan was obtained. Genetic
information and lung function test measurements were
available on 1725 subjects (754 males and 971 females).
Questionnaire
The respiratory questionnaire collected information on
demographics, medical history, personal smoking history
and household smoking. Information on exposure to
grain dust was identified by history of grain farming or
handling grains.
Pulmonary function testing
Pulmonary function test variables forced vital capacity
(FVC [L]), forced expired volume in one second (FEV1
[L]), forced expiratory flow at 25%-75% vital capacity
(FEF25-75 [L/sec]), and ratio of FEV1 to FVC (FEV1/FVC
[%]) were conducted using MedGraphics CPF-S system,
(Medical Graphics Corp. St. Paul, MN 55127, 1992),
according to American Thoracic Society criteria[19]. Per-
cent expected values for pulmonary function test variables
were derived from the equations of Crapo et al.[20]
DNA isolation and genotyping
Blood samples were collected in Qiagen PAXgene tubes.
Blood cards were spotted for each sample (S&S, catalog
#10538414) [21]. DNA was isolated on a Gentra Autopure
robot (Qiagen Corporation, Hilden, Germany), quantified
by UV spectrophotometry, and stored at -80°C. Working
dilutions of DNA at a concentration of 10 ng/ul were pre-
pared for genotyping. TaqMan allelic discrimination
assays for human TLR4 Asp299Gly polymorphism was
designed using Primer Express software (Applied Biosys-
tems, Foster City CA). Fluorescent probes were ordered
with minor groove binding (MGB) protein and non-fluo-
rescent quencher (NFQ). Plasmids carrying mutant (299)
and wild type sequences were diluted to a concentration
of 20 fg/ul as controls. Primer and probe concentrations
were optimized using control plasmids as templates. Taq-
Man genotype was determined by post-amplification
plate reading on an ABI Prism 7900 Sequence Detection
System (Applied Biosystems). Assays were not available on
demand at that time, therefore they were custom
designed. The assay was titrated for optimal performance,
so the concentration information is important. Sequence
and concentration information for HTLR4 299 TqaMan
Assays is as follows:
Oligonucleotide Sequence Conc. (nM)
D299G wildtype TET-CCTCGATGATATTATT-
MGBNFQ 900
D299G mutant FAM-CCTCGATGGTATTAT-
MGBNFQ 50BMC Pulmonary Medicine 2009, 9:46 http://www.biomedcentral.com/1471-2466/9/46
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299 forward
primer GAAGAATTCCGATTAGCATACTTAGACTACT 2
00
299 reverse
primer TAATTCTAAATGTTGCCATCCGAA 200
DNA samples that failed to genotype in two assays were
submitted for sequencing by fluorescent dye termination
sequencing.
Data Analysis
Descriptive statistics were expressed as mean ± S.E. Com-
parisons of demographic characteristics between any two
groups were conducted by using two-tailed Student's t-test
or Pearson's Chi-square test. Multiple linear regression
analysis was conducted to determine associations
between TLR4 Asp299Gly polymorphism and lung func-
tion measurements after adjusting for age, height, sex and
smoking. Statistical analyses were performed using SPSS
(SPSS Inc, Chicago, IL). In order to investigate the associ-
ation between TLR4 Asp299Gly polymorphism and lung
function, adjusting for other potentially important covari-
ates, the univariate analysis was conducted to determine
the candidate variables for the multivariable model [22].
Variables with p-value < 0.20 were selected for the multi-
variable linear analysis.
Results
For TLR4 299, 86.4%, were Asp299Asp, 13.4% were
Asp299Gly, and 0.2% were Gly299Gly [Rennie DC, Chen
Y, Pahwa P, Burch LH, Bharadwaj L, Grover VK, Schwartz
DA, Dosman JA: Gender-related associations between
toll-like 4 receptor 299 polymorphism and respiratory
outcomes, submitted]. The allelic frequencies for the TLR4
Asp299Gly polymorphism were Asp = 93.0% and Gly =
7.0%. The Hardy-Weinberg test for equilibrium was met
(p > 0.05).
Demographic characteristics of the study population strat-
ified by sex are shown in Table 1. As demonstrated, there
were no differences in mean values for age between males
and females. Compared to males there were more females
in the BMI category <25 kg/m2. The proportion of ever
smokers was significantly higher in males (52.4%) com-
pared to females (40.5%). TLR4 Asp299Gly frequency was
15.8% for males and 11.9% for females. Significantly
more males (59.5%) were exposed to grain dust com-
pared to females (23.1%).
Mean values for the pulmonary function test variables
FVC (L), FEV1(L), FEF25-75 (L/sec), and FEV1/FVC ratio are
shown in Table 2. These results are stratified by (i) sex
(male vs. female); (ii) smoking status (never smoker vs.
ever smoker) and (iii) TLR4299 genotype (wild type vs.
polymorphic). There was no difference in the observed
FEV1 and FVC values between never and ever smokers.
However, ever smokers had significantly lower predicted
FEV1 and FVC values compared to never smokers. Ever
smokers had significantly lower values for FEV1/FVC ratio
and FEF25-75 (both observed and predicted). Compared to
the wild type group, those with the polymorphic group
had significantly higher observed FEV1 and FVC. For other
observed or predicted lung function values, no differences
were observed between the wild type and polymorphic
groups.
Results of the univariate analysis are shown in Table 3.
Variables with p-value < 0.20 were included in the multi-
variable model. However, TLR4 Asp299Gly was a risk fac-
tor of primary interest, so it was kept in all the four final
models selected to draw conclusions (one model for each
of lung function outcome variable: FEV1, FVC, FEV1/FVC
ratio, FEF25-75). The significant predictors for FEV1 and
Table 1: Demographic characteristics and TLR4 Asp299Gly 
stratified by Sex
Sex
Male (n = 754) Female (n = 971)
Mean ± SE Mean ± SE
Age, yrs 51.7 ± 0.55 51.1 ± 0.51
Height, cm 175.5 ± 0.57 162.4 ± 0.51
Weight, Kg 89.8 ± 0.24 74.3 ± 0.20
n(%) n(%)
Age groups
< 40 years 180 (23.9%) 246 (25.3%)
40-59 years 320 (42.4%) 393 (40.5%)
≥ 60 years 254 (33.7%) 332 (34.2%)
Body Mass Index (Kg/m2)
< 25 132 (17.5%) 289 (32.7%)*
25-30 343 (45.5%) 301 (34.1%)
>30 279 (37.0%) 293 (33.2%)
Smoking Status
Never Smoker 359(47.6%) 578 (59.5%)*
Ever Smoker 395 (52.4%) 393 (40.5%)
TLR4299
Wild-type 635 (84.2%) 855 (88.1%)†
Polymorphic 119 (15.8%) 116 (11.9%)
Grain Dust
Not Exposed 305 (40.5%) 747 (76.9%)*
Exposed 449 (59.5%) 224 (23.1%)
Household Smoking
Not Exposed 677 (89.8%) 846 (87.1%)
Exposed 77 (10.2%) 125 (12.9%)
* p < 0.001; † p < 0.05BMC Pulmonary Medicine 2009, 9:46 http://www.biomedcentral.com/1471-2466/9/46
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Table 2: Observed mean value ± standard error and mean values of the % predicted ± standard error for the pulmonary function test 
variables for sex, smoking status and TLR4 Asp299Gly
Sex Smoking Status# TLR4 299#
Male (n = 754) Female (n = 971) Never Smoker
(n = 937)
Ever Smoker
(n = 788)
Wild type (n = 1490) Polymorphic
(n = 235)
Observed FEV1(L) 3.78 ± 0.03 2.65 ± 0.02 3.21 ± 0.03 3.18 ± 0.03 3.18 ± 0.02 3.31 ± 0.06+
% predicted 98.44 ± 0.59 102.86 ± 0.54 102.47 ± 0.53 99.09 ± 0.60& 100.91 ± 0.43 101.01 ± 1.05
Observed FVC (L) 4.73 ± 0.04 3.39 ± 0.02 3.97 ± 0.04 3.98 ± 0.04 3.95 ± 0.03 4.14 ± 0.07+
% predicted 98.55 ± 0.55 103.24 ± 0.51 102.38 ± 0.50 99.77 ± 0.57& 101.10 ± 0.41 101.76 ± 0.97
Observed FEV1/FVC 0.80 ± 0.002 0.81 ± 0.002 0.81 ± 0.0.002 0.80 ± 0.0.002& 0.80 ± 0.002 0.80 ± 0.004
% predicted 99.96 ± 0.29 100.06 ± 0.25 100.39 ± 0.26 99.57 ± 0.27& 100.11 ± 0.20 99.44 ± 0.49
Observed FEF25-75(L/s) 3.82 ± 0.05 2.89 ± 0.03 3.36 ± 0.04 3.21 ± 0.04& 3.28 ± 0.03 3.37 ± 0.08
% predicted 101.28 ± 1.10 103.89 ± 1.06 105.64 ± 1.04 99.30 ± 1.13& 102.89 ± 0.82 101.80 ± 2.17
Note: Predicted values are adjusted for age and height.
* Comparison made between Male and Female p value < 0.05
** Comparison made between Male and Female p value < 0.10
+ Comparison made between wild type and polymorphic group p value < 0.05
&Comparison made between never smoker and ever smoker group p value < 0.05
# Separate prediction equations used for males and females.
Table 3: Univariate regression analysis (one variable at a time) for relationship between lung function and TLR4 wild-type and 
polymorphic groups
Lung Function Model I
FEV1
Model II
FVC
Model III
FEV1/FVC
Model IV
FEF25_75
Variable Parameter Estimate 
(SE)
Parameter Estimate 
(SE)
Parameter Estimate 
(SE)
Parameter Estimate 
(SE)
Age, yrs -0.033 (0.001)*** -0.036 (0.001)*** -0.001 (0.000)*** -0.041 (0.002)***
BMI‡ (reference is normal)
Overweight 0.074 (0.055) 0.134 (0.067)* -0.010 (0.004)* 0.057 (0.075)
Obese -0.060 (0.057) -0.106 (0.069) 0.003 (0.004) 0.096 (0.077)
Smoking status 
(reference is never 
smoker)
Ever smoker -0.032 (0.044) 0.012 (0.054) -0.011 (0.003)** -0.151 (0.060)*
Sex (reference is female)
Male 1.031 (0.037)*** 1.336 (0.044)*** -0.011 (0.003)** 0.934 (0.056)***
TLR4299 
(reference is wild-type)
polymorphic groups 0.134 (0.064)* 0.185 (0.078)* -0.002 (0.004) 0.091 (0.088)
Grain Dust 
(reference is not exposed)
Exposed 0.299 (0.045)*** 0.426 (0.054)*** -0.011 (0.003)** 0.214 (0.061)**
Household Smoking 
(Reference is No)
Yes 0.021 (0.069) 0.001 (0.083) 0.004 (0.005) 0.037 (0.093)
*** p < 0.001; ** p < 0.01; * p < 0.05
‡Normal: <25; Overweight: 25-30; Obese: >30BMC Pulmonary Medicine 2009, 9:46 http://www.biomedcentral.com/1471-2466/9/46
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FVC were: age, smoking status, and TLR4 299 genotype
(see Table 4). For FEV1, BMI achieved borderline signifi-
cance. For FEV1/FVC ratio and FEF25-75significant predic-
tors were: age smoking status, and sex. BMI was an effect
modifier for the relationship between TLR4 Asp299Gly
and FEV1/FVC ratio and FEF25-75. For different categories
of BMI, the relationship between (i) TLR4 Asp299Gly and
FEV1/FVC ratio, and (iii) TLR4 Asp299Gly and FEF25-75 are
shown in Figures 1, and 2 respectively. Due to multiple
comparisons, adjustment in p-values (0.05/3 = 0.01667
was used for statistical significance) was made based on
the Bonferroni correction.
Discussion
In this study we investigated the association between
TLR4 Asp299Gly polymorphism and the lung function in
a community population. Based on the multivariable sta-
tistical analysis, this cross-sectional study showed that
TLR4 Asp299Gly was a potential risk factor for reduced
FEV1/FVC and FEF25-75 in obese subjects (BMI ≥ 30 kg/
m2). Earlier studies have shown: (i) an association
between obesity and reduced lung function [12-
15,23,24]; (ii) metabolic syndrome and impaired lung
function [16,17]; (iii) no association between TLR4 poly-
morphism and metabolic syndrome and diabetes [10,11];
and (iv) controversial relationship between TLR4 poly-
morphism and lung function [2-7,9,25]. The most impor-
tant finding of this report is that BMI appears to be an
effect modifier in the relationship of TLR4 polymorphism
and lung function. Based on the multivariable analysis: (i)
Table 4: Multiple regression analysis for relationship between lung function and TLR4 wild-type and polymorphic groups, adjusting for 
age, BMI, sex and smoking
Lung Function FEV1 FVC FEV1/FVC FEF25_75
Variable Parameter Estimate (SE) Parameter Estimate (SE) Parameter Estimate (SE) Parameter Estimate (SE)
Age, yrs -0.033 (0.001)*** -0.036 (0.001)*** -0.001 (0.000)*** -0.041 (0.002)***
BMI (reference is normal: <25)
Overweight (BMI: 25-30) 0.019 (0.035) 0.026 (0.042) -0.00002 (0.004) 0.065 (0.064)
Obese (BMI: >30) -0.057 (0.035) -0.145 (0.043)** 0.015 (0.004)*** 0.232(0.065)***
Smoking status 
(reference is never smoker)
Ever smoker -0.074 (0.027)** -0.056 (0.033) -0.007 (0.003)* -0.176 (0.047)***
Sex (reference is female)
Male 1.059 (0.028)*** 1.367 (0.034)*** -0.010 (0.003)** 0.959(0.048)***
TLR4299 (reference is wild-type)
polymorphic groups -0.020 (0.039) 0.003 (0.048) 0.007 (0.009) 0.062 (0.135)
Interactions
BMI and TLR4299
(reference is < 25 BMI and Wild type)
25-30 BMI group and polymorphic 
group
-0.008 (0.011) 0.040 (0.172)
>30 BMI group and polymorphic 
group
-0.021 (0.011)# -0.432 (0.175)*
*** p < 0.001; ** p < 0.01; * p < 0.05 # p < 0.10
Association between TLR4 genotype and FEV1/FVC ratio by  BMI categories (error bars represent 95% confidence inter- vals around the mean) Figure 1
Association between TLR4 genotype and FEV1/FVC 
ratio by BMI categories (error bars represent 95% 
confidence intervals around the mean).
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the variant group had a significantly higher mean pre-
dicted FEV1/FVC ratio in the BMI category < 25 compared
to the wild type group; (ii) no difference between wild
type and variant groups in the BMI category 25 - <30; and
(iii) the polymorphic group had lower mean predicted
FEV1/FVC ratio compared to the wild type group in the
BMI category ≥ 30. Conversely, the wild type group had
significantly lower mean value of predicted FEF25-75 in
BMI category 25 - <30 and significantly higher mean value
of FEF25-75 in the BMI category ≥ 30 compared to the pol-
ymorphic group.
In a recent study by Pistelli et al. [23] it was reported that
the "becoming obese" and "always obese" categories had
a significantly greater decline in lung function than "never
obese" group. In the "always obese" group, this was true
for vital capacity but not for FEV1. In our report, we did
not observe any significant interaction between BMI and
TLR4 gene for FVC and FEV1. However the relationship
between obesity (in terms of BMI) and lung function indi-
ces FEV1/FVC ratio and FEF25-75 was different between
wild type and polymorphic groups. In another recent
study, Rohde et al. [25] reported that the frequency of
TLR4 Asp299Gly polymorphism is decreased in COPD
patients. Cross-sectional analysis of our database did not
show any association between TLR4 polymorphism and
COPD. Reasons for the lack of association between TLR4
polymorphism and COPD may be either a small sample
size or a low frequency of TLR4 Asp299Gly polymor-
phism in the study population. To examine completely
the role of TLR4 Asp299Gly polymorphism, large popula-
tions or longitudinal studies are required to give adequate
statistical power to test the hypothesis of association
between this TLR4 polymorphism and COPD.
Santos et al suggest that it is unlikely that TLR4 Asp299Gly
polymorphisms have a major influence on adiposity,
bone mineral density or osteoporosis status in Chilean
elderly women [10]. A similar finding of no association
between TLR4 Asp299Gly and metabolic syndrome or
diabetes was observed by Illig et al. [11] Research has
shown that obesity affects the mechanics and physiology
of the respiratory system and people with higher BMI
[18,23] and waist circumference [17] are more likely to
have lower values for FEV1, FVC and higher values for
FEV1/FVC ratio. A study conducted in Taiwan reported
that obesity and metabolic syndrome were associated
with impaired lung function in an adult population [16].
It was suggested by the authors that obesity and insulin
resistance may be the common pathways underlying lung
function impairment and metabolic syndrome [16]. Shen
et al. reported that waist circumference correlates with
metabolic syndrome and other health risk indicators, fol-
lowed by BMI [17]. The authors also reported that while
percent fat is a useful indicator of overall adiposity, health
risks are best represented by the simply measured waist
circumference [17]. In a recent study, Ochs-Balcom et al.
[24] reported that abdominal adiposity is a better predic-
tor of pulmonary function than weight or BMI. The etiol-
ogy of metabolic syndrome is complex, which is
determined by the interplay of genetic and environmental
factors [26]. Yamada et al identified a genetic polymor-
phism that conferred susceptibility to metabolic syn-
drome [26]. Illig et al. reported that there is no impact of
TLR4 polymorphism on major features of metabolic syn-
drome [11]. According to the National Cholesterol Educa-
tion Program's Adult Treatment Panel III report (ATP III)
metabolic syndrome can be identified clinically based on
the five components: abdominal obesity, given as waist
circumference (for men > 102 cm and for women > 88
cm); triglycerides (≥ 150 mg/dL); high-density lipoprotein
choelstrol (< 40 mg/dL); blood pressure (≥ 130/≥ 85 mm
Hg) and fasting glucose (≥ 110 mg/dL). Abdominal obes-
ity is most strongly associated with the metabolic syn-
drome [27]. In our study, information on all the five
components of metabolic syndrome was not available to
us, hence, when we conducted the statistical analysis by
replacing BMI with waist circumference in multivariable
models, and similar results were obtained.
Association between TLR4 genotype and FEF25-75 by BMI cat- egories (error bars represent 95% confidence intervals  around the mean) Figure 2
Association between TLR4 genotype and FEF25-75 by 
BMI categories (error bars represent 95% confidence 
intervals around the mean).
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In our study TLR4 Asp299Gly frequency was 15.8% for
males and 11.9% for females, so it was of interest to
explore the three-way interaction between sex, TLR4 and
BMI. A 3-way crosstab analysis showed that there may be
a potential three-way interaction between sex, TLR4
Asp299Gly polymorphism and BMI. There was no signif-
icant difference in the mean values of FEV1 and FVC for
wild and variant groups when stratified by sex. Mean val-
ues for predicted FEV1/FVC ratio were (i) significantly
higher in variant group (males: 80.9 ± 0.02, females: 81.8
± 0.02) compared to the wild type (males: 79.9 ± 0.02,
females: 80.8 ± 0.02) in BMI category <25 kg/m2 and (ii)
significantly lower for the variant group (males: 79.5 ±
0.02, females: 80.6 ± 0.02)) compared to the wild type
group (males: 80.6 ± 0.02, females: 81.6 ± 0.02) in BMI
category ≥ 30 kg/m2. Mean values for predicted FEF25-75
were (i) significantly higher for the variant group (males:
3.93 ± 0.69, females: 3.71 ± 0.63) compared to the wild
type group for BMI category 25 - < 30 kg/m2 ; and (ii) sig-
nificantly lower in the variant group (3.62 ± 0.68) com-
pared to the wild type group (3.89 ± 0.63) in BMI category
≥ 30 kg/m2. The association between TLR4 Asp299Gly
polymorphism and FEF25-75 was not modified by BMI for
females. However, this three-way interaction was not sig-
nificant in the multivariable regression model, possibly
due to a relatively low prevalence of TLR4 Asp299Gly in
the study population.
This study had some methodological strengths and as well
as weaknesses. The pulmonary function tests were admin-
istered by trained nurses using techniques which con-
formed to ATS standards. The pulmonary function tests
were reviewed by a respiratory physician. A weakness of
this study was that the number of the subjects was too
small to conduct comparisons among three groups
(Asp299Asp, Asp299Gly and Gly299Gly). For TLR4 299,
86.4%, were Asp299Asp, 13.4% were Asp299Gly, and
0.2% were Gly299Gly [Rennie DC, Chen Y, Pahwa P,
Burch LH, Bharadwaj L, Grover VK, Schwartz DA, Dosman
JA: Gender-related associations between toll-like 4 recep-
tor 299 polymorphism and respiratory outcomes, submit-
ted]. We therefore combined the last two groups. The
allele frequencies of single nucleotide polymorphisms,
such as Asp299Gly, vary between different ethnic popula-
tions. The TLR-4 Asp299Gly polymorphism has different
minor allele frequencies in, for example, 0% in Chinese,
6.5% in American and 9.8% in West African populations
[28]. 93% of our study subjects were Caucasians; 0.4%
were aboriginal; 1.4% had reported other ethnicity, and
for 5.3% subjects ethnicity was missing. We were unable
to define the presence/absence of metabolic syndrome
due to lack of information on all the five components of
metabolic syndrome and hence conducted our analysis
using BMI (and repeated statistical analysis using waist
circumference [results not shown]).
Overall, our study was adequately powered to detect clin-
ically meaningful differences. To our knowledge this is the
first study which showed that BMI is an effect modifier in
the relation of TLR4 Asp299Gly polymorphism and lung
function (FEV1/FVC ratio and FEF25-75). More studies are
needed to accumulate the evidence of this effect modifica-
tion and to assess the credibility [29] of this association. It
is essential to understand and investigate the interplay
between lung function, TLR4 Asp299Gly polymorphism
and metabolic syndrome in humans. TLR4 itself is not
associated with lung function but has opposing effects at
extremes of BMI. The mechanism is unknown to explain
these opposing effects. Further studies should investigate
the role of TLR4 Asp299Gly and additional polymor-
phisms of TLR4 to understand the potential effects of
innate immunity on lung function in relation to meta-
bolic syndrome. It will be important to investigate
whether or not TLR4 Asp299Gly linked to another genetic
modifier of the metabolic syndrome. The association of
TLR4 Asp299Gly variant status and lung function should
be replicated in more than one population in order to
establish the importance of this finding.
Conclusion
BMI may modify the associations of TLR4 Asp299Gly pol-
ymorphism with FEV1/FVC ratio and FEF25-75. The associ-
ation of TLR4 Asp299Gly variant status and lung function
should be analyzed in more than one population in order
to establish the importance of this finding.
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